Preclinical News and Research

RSS

Xuebijing injection reduces inflammation and ferroptosis in acute lung injury

Using an LPS-induced ALI mouse model and LPS-stimulated alveolar macrophages, they found XBJ reduced inflammatory cytokine surges, preserved alveolar barrier integrity, and limited tissue injury, while probing the molecular pathways and intracellular targets underlying these benefits.

7 Apr 2026

Review identifies TREM-1 as key amplifier of inflammatory diseases

Published in Current Molecular Pharmacology, a comprehensive review by Eman R. Al Sawy and colleagues from Cairo University consolidates evidence on the triggering receptor expressed on myeloid cells-1 (TREM-1) as a central amplifier of inflammatory responses.

7 Apr 2026

New obesity definition could delay treatment and widen health gaps

The Lancet obesity framework aims to improve risk assessment but risks delaying treatment and deepening health inequities, according to recent evaluations.

7 Apr 2026

Could vitamin D in midlife protect your brain from early Alzheimer’s?

Higher serum vitamin D in midlife is associated with reduced tau burden in the brain, highlighting its potential role in early dementia risk assessment.

7 Apr 2026

New technique can simultaneously treat lung cancer and muscle-wasting condition

Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it.

6 Apr 2026

Prickly pear may pack a surprising punch against metabolic syndrome

This narrative review examines how Opuntia ficus-indica fruit, or prickly pear, may help target multiple features of metabolic syndrome through its fiber, betalains, polyphenols, carotenoids, and other bioactive compounds. The authors conclude that the fruit shows promising mechanistic and preclinical potential, but stronger human trials are still needed before firm clinical claims can be made.

6 Apr 2026

How gut microbes may shape heart attack damage and recovery

This review argues that gut microbes and the metabolites they produce, especially SCFAs and TMAO, may shape how the heart responds to myocardial infarction through epigenetic pathways such as DNA methylation, histone modification, and non-coding RNAs. It also outlines potential intervention routes, including diet, probiotics, postbiotics, and metabolite-targeted therapies, while noting that much of the evidence remains translational and not yet clinically definitive.

6 Apr 2026

Mayo Clinic researchers develop experimental nanotherapy to treat aggressive brain tumors

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, according to a study published in Communications Medicine.

6 Apr 2026

Metformin mimics exercise-related metabolic effects in prostate cancer patients

A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive.

6 Apr 2026

Boosting mitochondrial function in dendritic cells can improve cancer immunotherapy

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer - and how restoring their energy production can improve immunotherapy. Dendritic cells activate the cytotoxic immune cells that destroy cancer.

2 Apr 2026

New obesity definition may delay treatment and complicate diagnosis

Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health problems may complicate diagnosis and delay treatment, according to an Endocrine Society guideline communication published in The Journal of Clinical Endocrinology & Metabolism.

2 Apr 2026

International researchers set new standards for studying tumor microbiota

Recent research shows that tumors in different organs host microbial communities capable of influencing cancer biology, immune responses, and the effectiveness of therapies, highlighting the need to standardize methods for studying intratumoral microbes.

2 Apr 2026

Celiac disease weakens gut microbes that digest fiber

Findings suggest that impaired fiber metabolism in celiac disease is due to microbial deficits, not just diet, emphasizing the need for targeted interventions.

2 Apr 2026

Highly potent opioid shows potential as therapy for pain and opioid use disorder

Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as a therapy for both pain and opioid use disorder.

1 Apr 2026

Gut bacteria determine fiber benefits in celiac disease patients

Many people with celiac disease are advised to eat more fiber to support digestion and manage symptoms, either through diet or prescribed fiber supplements.

31 Mar 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Gene signature maps cholangiocarcinoma subtypes for precision treatment

Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly concealed and heterogeneous nature.

31 Mar 2026

Broken String Biosciences rebrands to reflect strategic evolution as demand grows for unbiased genome-wide off-target analysis

Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today introduced new branding and comprehensive website as part of its strategic repositioning.

From Broken String Biosciences 31 Mar 2026

New genetic ‘roadmap’ advances precision therapy for intrahepatic cholangiocarcinoma

The 1,341-gene signature for intrahepatic cholangiocarcinoma offers a framework for precise diagnosis and tailored therapies, addressing tumor heterogeneity.

From BGI Genomics 31 Mar 2026

How gut imbalance may drive obesity, diabetes, and heart disease

A new review argues that gut dysbiosis is closely linked to metabolic dysfunction through intertwined effects on inflammation, oxidative stress, gut barrier integrity, microbial metabolites, and epigenetic regulation. It also highlights microbiome-targeted strategies such as high-fiber diets, probiotics, prebiotics, postbiotics, exercise, and fecal microbiota transplantation as promising ways to support metabolic health.

30 Mar 2026